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Abstract
This review provides an overview of studies employing particle-mediated epidermal delivery (PMED) or the gene gun to administer
DNA vaccines for infectious diseases in preclinical studies employing large animal models and in human clinical trials. It reviews the
immunogenicity and protective eYcacy of PMED DNA vaccines in nonhuman primates and swine and studies that have directly com-
pared the eVectiveness of PMED in these large animal models to existing licensed vaccines and intramuscular or intradermal delivery of
DNA vaccines with a needle. Various clinical trials employing PMED have been completed and an overview of the immunogenicity,
safety, and tolerability of this approach in humans is described. Finally, eVorts currently in progress for commercial development of
particle-mediated DNA vaccines are discussed.
© 2006 Elsevier Inc. All rights reserved. 
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1. Introduction
DNA vaccines were introduced over 14 years ago as a
novel method for vaccination [1,2] and showed consider-
able promise in rodents through the induction of robust
cytotoxic T cell responses and antibody and protection
against a wide variety of infections [3]. However, studies
employing a needle to inject DNA vaccines into the muscle
or dermis proved to be disappointing in larger animals and
humans, producing only sporadic, low levels of immune
responses despite the use of over 1000-fold higher doses of
DNA than what had proved to be eVective in rodents [4].
Because early clinical trials showed less than optimal
immunogenicity, development of methods that increase
DNA vaccine potency has been a primary focus of research
in this area in more recent years. These eVorts have
included improvements in vector design [5–8], the use of a
viral vectored or protein vaccines to boost DNA-primed
responses (i.e. prime-boost regimens) [9–11], formulation
with adjuvants or cytokines [12–14], and improved DNA
vaccine delivery methods [15–17]. In this review, we discuss
the progress of particle-mediated epidermal delivery of
DNA vaccines with an emphasis on its eVectiveness in pre-
clinical studies in large animal models (nonhuman primates
and swine) and human clinical trials.
2. Particle-mediated epidermal delivery of DNA vaccines
Particle mediated epidermal delivery (PMED) also
called the “gene gun”, involves the use of a needle-free
device that delivers gold particles coated with DNA plas-
mids encoding vaccine antigens into the epidermal layer of
the skin. PMED diVers from intramuscular or intradermal
injection of DNA with a needle and syringe in that it
results in direct delivery of the vaccine into the intracellular
environment [18]. The DNA is delivered into both non-
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professional APCs (i.e. keratinocytes) and professional
antigen presenting cells (i.e. Langerhans cells) of the viable
epidermis [19,20]. Since the earliest DNA vaccine studies,
direct comparisons of PMED to needle-based approaches
for DNA vaccine delivery in mice [21–27] and monkeys
[28–31] have shown that PMED can induce higher anti-
body and/or CD8+ T cell responses with substantially lower
doses (100–1000-fold) of DNA. The eVectiveness of this
system is likely related to the use of a delivery technology
that deposits DNA directly into cells [18,20] as well as the
immune competence of the epidermis as a delivery site
[32,33]. These features are also believed to be responsible
for the ability of this technology to induce robust levels of
immune responses in both small and large animals with
very small doses (i.e. 1–10g) of DNA.
3. Optimization of PMED in large animal preclinical models
The earliest large animal studies employing the Powder-
Med (formally PowderJect) delivery device for PMED were
in nonhuman primates and required 5–7 doses to induce a
signiWcant immune response [34–36]. However, optimiza-
tion of the delivery device [37], vaccine vectors [38], and
immunization regimens [26,38] substantially improved this
technology so that later studies employing a clinical
research device achieved robust and protective levels of
immunity in nonhuman primates after only 1–3 doses
[29,30,39,40]. Recent studies have shown that the delivery
device employed can inXuence the immunogenicity of
PMED in nonhuman primates. The Bio-Rad Helios device
has been used in nonhuman primates and shown to require
45–60g of DNA administered over 45+ sites to induce a
signiWcant response in 100% of the immunized animals
[41,42]. This result may be due to diVerences in the delivery
footprint of the two devices. The PowderMed device used
in nonhuman primates delivers 8-fold more DNA-coated
gold particles into a larger delivery site than the Bio-Rad
device (DH Fuller, unpublished).
The nonhuman primate immune system is considered
the best animal model for predicting the immunogenicity of
a vaccine in humans. However, the skin of monkeys is sig-
niWcantly diVerent from humans, being thinner and not
attached to the underlying muscle. Pig skin is very similar in
both structure and thickness to human skin [43], and the
swine has been the model of choice for preclinical studies
designed to optimize PMED delivery parameters and toler-
ability in the skin.
4. PMED DNA vaccines for HIV/SIV in nonhuman primates
PMED DNA vaccines expressing HIV or SIV genes
have been tested in nonhuman primates alone (Table 1) and
in combination with recombinant protein or viral vectored
vaccines in a prime-boost regimen (heterologous boosting)
(Table 2). Heterologous boosting substantially increases the
immunogenicity of PMED DNA vaccines. However, it is
not clear at this time if it improves protection since partial
(i.e. durable virus load reduction or delay in disease pro-
gression) to complete (i.e. prevention of infection or dis-
ease) protection has been achieved with (Table 1) and
without (Table 2) boosting. Studies that have directly com-
pared PMED alone or in combination with heterologous
boosting are not consistent. In one study, boosting with a
recombinant vaccinia virus substantially increased anti-
body responses but was less eVective than PMED DNA
vaccination alone in reducing viral load and delaying dis-
ease following intravenous infection with a primary isolate
of SIV [35]. In a second study, vaccinia boosting was clearly
superior to PMED DNA vaccination alone in protection
against a pathogenic SHIV89.6P challenge with respect to
reduction in virus load and protection from disease [44].
With few exceptions [45,46], PMED DNA vaccines have
consistently induced at least transient viral containment
and partial to complete protection against AIDS viruses in
nonhuman primates (Table 1). In one study, a PMED
DNA vaccine prime followed by boosting with a recombi-
nant fowlpox virus vaccine aVorded complete protection
against a nonpathogenic HIV infection [47]. In another
study, a PMED DNA vaccine in the absence of heterolo-
gous boosting protected 4/7 macaques from infection and/
or disease following challenge with a highly pathogenic pri-
mary SIV isolate [48]. More recently, PMED has also been
eVectively used for immunotherapeutic DNA vaccination
in combination with antiretroviral therapy in SIV-infected
macaques. In this study, a PMED DNA vaccine eVectively
boosted virus-speciWc T cell responses, reduced viral load
during drug therapy, and then maintained containment of
viremia for 6 months to 1 year (the duration of the study)
even after the antiretroviral drug was removed [49].
The immune mechanisms responsible for preventing or
controlling HIV are not clear. However, much evidence
suggests a critical role for CD4+ and CD8+ T cell responses
[50,51]. Nonhuman primate studies have shown that parti-
cle-mediated HIV/SIV DNA vaccines alone (Table 1) or in
combination with heterologous boosting (Table 2) eVec-
tively induce CD8+ T cells responses. CD4+ T cell responses
are also induced and where tested, the nature of this
response was shown to be predominantly Th1 [47,48], a
type of T helper response that produces IFN and TNF
cytokines and is associated with stronger CD8+ T cell
responses. This result is in contrast to earlier studies con-
ducted in mice that showed PMED DNA vaccines induced
predominantly a Th2 response [52–56], and demonstrates
that the nature of the immune response induced by a
vaccine in mice does not predict the outcome in nonhuman
primates.
An eVective vaccine against AIDS will need to protect
against sexual transmission and may require a vaccine that
induces mucosal immune responses at the site of exposure.
The skin can function as an eVective inductive site for
both mucosal and systemic immune responses [57,58],
and administration of vaccines to the skin by PMED
induces immune responses in both the blood and mucosal
compartments [48,59]. In one study, an SIV DNA vaccine
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administered by PMED induced mucosal immune
responses in the gut of rhesus macaques and prevented a
disseminated infection at the site of exposure following
intrarectal challenge with a primary isolate of SIV [48,59].
This result demonstrated the ability of PMED to induce
mucosal immunity in a large animal and suggested a role
for mucosal responses in protection against HIV.
To date, the collective results in nonhuman primate
models for AIDS show that PMED DNA vaccines induce
relevant responses and can exert signiWcant control of
AIDS viruses. Taken together, these data support PMED
as a promising approach for prophylaxis or therapy of
HIV.
5. Particle-mediated DNA vaccines for emerging infectious 
diseases in nonhuman primates
5.1. Flaviviruses
PMED studies in nonhuman primates have been con-
ducted with DNA vaccines for the Xaviviruses tick-borne
encephalitis virus, (TBEV) Japanese encephalitis virus
(JEV), and Dengue virus (DENV) [40,42,60] (Table 3). Pro-
tective immunity to Xavivirus infections generally correlates
with a neutralizing antibody response to the envelope gly-
coprotein (E). The E protein arises by cleavage of a precur-
sor, preM/E.
DNA vaccines encoding the preM/E genes of two strains
of TBEV were evaluated in cynomolgus macaques in com-
parison to a formalin-inactivated subunit vaccine that is
commercially available in Europe [40]. Monkeys were given
three vaccinations of approximately 10g of the DNA
vaccines by PMED or were given three vaccinations of the
formalin inactivated vaccine at the human dose at days 0,
30 and 70. All of the vaccines elicited neutralizing antibod-
ies in the monkeys, with the antibody responses persisting
for at least 15 weeks after the third vaccination. Mice but
not monkeys suVer uniformly fatal infections with TBEV;
consequently, the protective eYcacy of the PMED DNA
vaccines was evaluated by passive transfer of monkey sera
to mice and challenge of the mice. Complete protection of
mice to challenge with either strain of TBEV was found to
correlate with the neutralizing antibody titer of the monkey
sera [40].
Table 1
Particle-mediated DNA vaccines for HIV/SIV in nonhuman primates: Studies without protein or viral vector boosting
a Rhesus macaque.
b Reference.
Pathogen DNA vaccine Species Immunogenicity Challenge virus, protective eYcacy and 
comments
Ref.b
Binding 
antibody
Neutralizing 
antibody
CD8 CD4 Mucosal
SIV SIV Env, virus-like 
particles
Rhesusa Yes Yes Yes nd nd Homologous intravenous SIVmac251. 
Reduction in plasma antigenemia but not cell-
associated virus in 3/3
[36]
SIV SIVgp120 Rhesus Yes Yes nd nd nd Induced cross-neutralizing antibody against 2 
primary isolates of SIV
[34]
SIV SIVgp120 Rhesus Yes nd nd nd nd Increasing the rest period between doses 
increases immunogenicity of DNA 
immunization in macaques
[38]
SIV SIVgp120, SIVgp160 Rhesus Yes Yes nd nd nd Heterologous, intravenous SIV/B670. Virus 
load reduced and CD4 decline delayed in 3/3
[35]
SIV Expression libraries 
alone or co-delivered 
with GM-CSF and IL-12
Rhesus Yes nd Yes Yes nd Homologous, intravenous SIVmac251. 
Transient VL reduction and delayed disease 
progression in 2 of 3 groups. Co-delivery of 
GM-CSF and IL-12 cytokines in the 3rd group 
enhanced infection and disease
[79]
SIV SIV gag, pol, env Rhesus Yes nd Yes Yes (Th1) Yes (IgG, 
IgA, CTL)
Heterologous, intrarectal SIV/B670, Virus 
loads low to undetectable and protection 
against disease in 4/7
[48]
HIV-2 Expression library Babboon Yes Yes Yes Yes nd Prechallenge antibody and CMI detectable but 
low. Homologous, intravenous HIV-2 
challenge. 0/2 protected. No evidence of virus 
load reduction
[45]
SIV SIV CTL epitopes, gag, 
tat
Rhesus nd nd Yes Yes nd Therapeutic vaccine study. Immunization of 
SIV/B670-infected animals during 
antiretroviral drug therapy (ART) prevented 
viral rebound and disease after ART was 
withdrawn in 17/20 vaccinated animals that 
responded well to ART
[49]
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Table 2
Particle-mediated DNA vaccines for HIV/SIV in nonhuman primates employing a protein or viral vector boost
a Rhesus macaque.
b Cynomologus macaque.
c Pig-tailed macaque.
Pathogen DNA vaccine Prime Boost vaccine Species Immunogenicity Protective eYcacy and comments Ref.
Binding 
antibody
Neutralizing 
antibody
CD8 CD4 Mucosal
HIV HIV gag, pol, env Recombinant gp160 
protein
Rhesusa Yes Yes nd nd nd Induced cross-neutralizing antibody [34]
Heterologous nonpathogenic intravenous SHIV-
SF2. Transient reduction in acute VL in 3/5b
(Unpublished 
D Fuller)
SIV SIV env Vaccinia virus Rhesus Yes Yes nd nd nd Heterologous, intravenous SIV/B670, 100–200-
fold VL reduction and delayed CD4 decline 
in 3/3
[35]
SHIV HIV env, gag, tat, nef, 
rev
Recombinant Env 
(gp160), Gag,Tat, 
Nef, Rev protein
Cynob Yes Yes nd Yes nd Neutralizing antibody against HIVLAI and 
SHIV-4. No evidence of protection following 
intravenous infection with homologous SHIV-4
[46]
HIV HIV env, gag Fowlpox virus Rhesus Yes nd Yes Yes (Th1) nd Homologous, nonpathogenic, intravenous 
HIVLAI. Protection from infection (no detectable 
plasma viremia) in 4/4
[47]
SHIV HIV env, SIV gag, pol MVA Rhesus Yes Yes Yes nd nd Homologous intrarectal SHIV 89.6P, sustained 
VL containment and protection from CD4 
decline in 1/4
[80]
SIV Single SIV gag CTL 
epitope
ModiWed Vaccinia 
Ankara (MVA)
Rhesus n/a n/a Yes nd nd Homologous SIV/mac251, intravenous. 
Protection from infection in 1/3
[81]
SIV Single SIV Gag CTL 
epitope
MVA Rhesus nd nd Yes nd nd Homologous, intrarectal SIVmac239 challenge. 
VL reduction in 2/8
[82,83]
SIV SIV Gag, Pol, Env, 
Rev, Tat, Nef, vif, vpx
MVA Rhesus nd Yes (low 
levels)
Yes Yes nd Homologous intrarectal SIVmac239. Transient 
VL reduction in 7/7
[84]
SIV 2 SIV CTL epitopes, 
SIV nef, tat
MVA Rhesus nd nd Yes Yes Yes (CD8, 
CD4)
Homologous intrarectal SIVmac239, transient 
VL reduction in 3/3
[85]
SHIV Env, Rev, Gag, Pol, 
Tat, Rev, Vif, Vpu/
Vpx, Vpr, nef 
Vaccinia virus Pig-tailedc Yes nd Yes nd nd Homologous SHIV89.6P, intrarectal. Sustained 
VL reduction and prevention of CD4 decline 
in 5/6
[44]
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Four distinct serotypes of dengue virus (DEN-1, DEN-2,
DEN-3 and DEN-4) cause human disease. There is no
cross-protective immunity in humans among the four sero-
types. Although monkeys do not mimic human dengue
infections, it is possible to measure viremia in monkeys
after challenge. A DNA vaccine expressing the preM/E
genes of DEN-2 delivered by PMED was shown to elicit
neutralizing antibodies in all three rhesus macaques receiv-
ing four 2g doses of DNA, in one of three monkeys
receiving two 1g vaccine doses, and in none of the three
monkeys receiving only one 1g vaccine dose [60]. Mon-
keys were challenged with DEN-2 virus one month after
the Wnal vaccination and monitored for viremia. In each of
the two groups receiving the highest doses of vaccine, two
monkeys had no viremia, and the third monkey had a single
day of viremia, as compared to 4.7 days of viremia in con-
trol monkeys. Partial protection from viremia was also
observed at 7 months after vaccination in additional
monkeys that received two 1g doses by PMED [60].
A JEV DNE vaccine expressing the viral preM/E genes
was evaluated in two cynomolgus macaques by PMED [42].
Monkeys were vaccinated three times at intervals of 4–6
weeks with 3g of DNA. Two weeks after vaccination,
the monkeys were challenged intranasally with JEV. Both
vaccinated monkeys developed neutralizing antibody
responses similar to those of two monkeys given an inacti-
vated JEV vaccine. After challenge, one of the two PMED-
vaccinated monkeys developed neurological symptoms and
was euthanized. The other showed a rise in neutralizing
antibodies and did not develop symptoms. The number of
monkeys in this study is insuYcient to draw any conclu-
sions or comparisons to other methods of delivery; how-
ever, the neutralizing antibody responses observed oVer
encouragement for further studies.
5.2. Filoviruses
A DNA vaccine expressing the surface glycoprotein (GP)
of the Wlovirus, Marburg virus (MARV), was evaluated in 6
cynomolgus macaques in two separate PMED experiments
[61]. In each study, three monkeys were vaccinated three
times at 4-week intervals with 20g DNA. All vaccinated
monkeys developed antibodies to MARV as measured by
ELISA. After subcutaneous challenge with MARV, all of
the monkeys developed fevers, indicating that they were
infected. In both experiments, two of three monkeys sur-
vived the challenge, showed no rises in liver enzymes and
had no detectable viremia (Table 3). The other monkey in
each study developed viremia and died, although in one
experiment, death was delayed as compared to a control
monkey [61]. These results suggest that the MARV GP vac-
cine, when delivered by PMED, is immunogenic in monkeys,
and can oVer potective immunity.
5.3. Hantaviruses
Hantaviruses are rodent-borne viruses that can
cause hemorrhagic fever with renal syndrome (HFRS) or
Table 3
Particle-mediated DNA vaccines for emerging infectious diseases in nonhuman primates
a Rhesus macaque.
b Cynomologus macaque.
Pathogen DNA vaccine Species Immunogenicity Protective eYcacy and comments Ref.
Binding 
antibody
Neutralizing 
antibody
Russian spring summer 
encephalitis (RSSE), 
Central European 
encephalitis (CEEV)
prM and E Rhesusa Yes Yes Neutralizing antibody induced by PMED was comparable 
to levels induced by commercially licensed vaccine. Passive 
transfer of sera from immunized macaques protected or 
partially protected mice challenged with RSSE and CEEV
[40]
Ebola (MARV) GP Cynob Yes nd Subcutaneous challenge with MARV. Survival and viral 
clearance in 4/6
[61]
Japanese encephalitis prM and E Cyno nd Yes Neutralizing antibody recall following intranasal challenge 
with Japanese encephalitis
[42]
Hepatitis E Full-length ORF of 
HEV
Cyno Yes nd Intravenous challenge with heterologous HEV [28]
No detectable virus in 3/3
Andes virus M gene of Andes 
virus (ANDV)
Rhesus Yes Yes Passive transfer of sera from immunized macaques 
protected hamsters from ANDV
[62]
Hantaan/Andes virus M genes of ANDV 
and HTNV
Rhesus Yes Yes Cross-neutralizing antibody against both HPS and HFRS 
hantaviruses. Long-term memory B cell response that 
exhibited rapid recall and broad neutralizing capacity to 
subsequent boosting 1year after the initial dosing
[63]
Dengue-2 PrM and E Rhesus nd Yes Intravenous challenge with Dengue-2. No detectable 
viremia or viremia present only 1 day post-challenge in 6/6 
macaques that received a minimum of 2 doses
[60]
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hantavirus pulmonary syndrome (HPS). DNA vaccines
expressing the two envelope glycoproteins, GN and GC of
the HFRS-causing hantavirus, Hantaan virus (HTNV), or
of the HPS-causing hantavirus, Andes virus (ANDV), were
evaluated in rhesus macaques. Two monkeys per group
received »6g of each of the HTNV or ANDV DNA vac-
cines by PMED at weeks 0, 3, and 6 and at week 9 or 12
[62]. Neutralizing antibodies were detected after the Wrst
vaccination and rose to very high levels after the Wnal vacci-
nation. Monkeys are not a lethal challenge model for han-
taviruses; however, hamsters will succumb to Andes virus
challenge and they can be infected by HTNV, although
they do not become ill. Consequently, to evaluate the pro-
tective eYcacy of the PMED-delivered HTNV and ANDV
DNA vaccines, sera from the vaccinated monkeys were
passively transferred to hamsters and the hamsters were
challenged with ANDV or HTNV. All hamsters that
received transferred sera from ANDV DNA-vaccinated
monkeys 4 or 5 days before challenge were protected from
the ANDV challenge (Table 3). Six of 8 hamsters given sera
from HTNV DNA-vaccinated monkeys showed no evi-
dence of infection after HTNV challenge, suggesting sterile
immunity [62]. In a follow-up study, monkeys were boosted
1–2 years after their initial vaccination series [63]. Very
strong anamnestic responses were observed in monkeys
given a single boost with either the ANDV or HTNV DNA
vaccines, with the monkeys developing neutralizing anti-
body titers higher than those achieved following the initial
vaccination series. In this same study, two monkeys were
vaccinated by PMED four times at 3-week intervals with a
DNA vaccine expressing the GN and GC genes of both
ANDV and HTNV [63]. These monkeys developed neutral-
izing antibodies to both viruses, albeit at lower levels than
the monkeys that received the individual HTNV or ANDV
DNA vaccines. The antibody responses could be boosted
dramatically by a single PMED vaccination at week 85.
These studies show that PMED vaccination can elicit
long-lived neutralizing antibody responses in nonhuman
primates that can be readily boosted with additional
vaccinations.
5.4. Hepatitis E virus
Hepatitis E is a non-enveloped positive strand RNA
virus, which has yet to be propagated in cell culture. Anti-
body responses to the capsid protein have been shown to
correlate with protective immunity. Three cynomolgus
macaques received 4 PMED vaccinations at 4-week inter-
vals of approximately 25g/dose of a DNA vaccine
expressing the capsid protein of HEV [28]. All three vacci-
nated monkeys developed antibody responses and were
protected from challenge with HEV (Table 3). HEV RNA
was not detected in the stool or serum samples of any of the
PMED-vaccinated and HEV-challenged monkeys. In con-
trast, control monkeys that received a mock DNA con-
struct or that received the vaccine by intradermal injection
did not develop antibodies to HEV and were not protected
from challenge [28]. These data show a clear correlation
between antibody responses and protection and point
toward potential development of a PMED-delivered DNA
vaccine for HEV.
6. Particle-mediated DNA vaccines as an alternative for 
existing vaccines: studies in nonhuman primates and swine
Several studies investigated particle-mediated DNA
vaccines as an alternative approach to existing vaccines and
directly compared PMED to licensed vaccines in either
nonhuman primates or swine (Table 4). In swine, 3 doses of
0.5–1.5g of a hepatitis B DNA vaccine administered by
PMED induced protective levels of antibody that were
comparable to levels induced with 3 doses of a licensed
recombinant protein vaccine [64]. Similarly, 2 doses of a
rabies DNA vaccine administered by PMED induced com-
parable antibody and protection against lethal infection
with rabies virus as a human diploid cell vaccine (HDCV)
[29]. A single dose of this rabies DNA vaccine also aVorded
post-exposure protection [65] and induced memory B cell
responses that aVorded protection 1 year post-immuniza-
tion [39]. These results demonstrate that particle-mediated
DNA vaccines can induce durable immunity and be eVec-
tively used for post-exposure prophylaxis.
Immunization of swine with an inXuenza DNA vaccine
[66] and monkeys with either a measles DNA vaccine [31]
or a smallpox DNA vaccine [67] by PMED induced anti-
body responses that were, on average, 2–10-fold lower than
the respective licensed killed whole virus vaccine for inXu-
enza, the Moraten live attenuated vaccine for measles, and
the DryVax vaccine for smallpox (Table 4). Nevertheless,
these DNA vaccines still provided signiWcant protection
from infection. In the inXuenza [66] and measles [31] stud-
ies, protection was similar to that provided by the licensed
vaccines, demonstrating that although PMED induced
lower immunogenicity than the existing vaccines, the levels
were still suYcient to aVord full protection.
In nonhuman primates, PMED has been directly com-
pared to parenteral delivery of DNA vaccines with a needle.
Where tested, PMED induced comparable CD8+ T cell
responses [31] and superior antibody [29–31] with 100–
1000-fold less DNA when compared to injection of naked
DNA into the skin or muscle with a needle. Similarly, in
swine, administration of a porcine RSV DNA vaccine by
PMED induced signiWcantly higher antibody responses
than a combined approach employing both intramuscular
and intradermal inoculation of naked DNA with a needle
[68]. PMED has also been shown to aVord superior protec-
tion against viral infections when compared to intramuscu-
lar or intradermal DNA delivery [29,31].
7. Human clinical trials
PMED has been tested in human clinical trials and is, to
date, the only DNA vaccine delivery method that has con-
sistently induced signiWcant humoral and cellular immune
92
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Table 4
Particle-mediated DNA vaccines as an alternative to existing vaccine strategies in preclinical studies in nonhuman primates and swine
a Rhesus macaque.
b Cynomologus macaque.
Pathogen DNA vaccine Species Immunogenicity Protective eYcacy and comments Comparison to existing vaccine Ref.
Binding 
antibody
Neutralizing 
antibody
CD8 CD4
Hepatitis B sAg Rhesusa Yes n/a nd nd Protective levels of antibody induced in 8/8 after 1–3 
doses of 4 g DNA
nd [30]
Hepatitis B sAg Swine Yes n/a nd nd Protective levels of antibody induced in 10/10 after 3 
doses of 0.5 or 1.5 g of DNA
Induced comparable levels of antibody 
when compared to immunization with a 
commercially available hepatitis B 
recombinant protein vaccine
[38]
Measles MV H and F 
glycoprotein
Rhesus Yes Yes Yes nd 2 doses of 8 or 16 g DNA induced protective levels of 
antibody and protected against intratracheal challenge 
with MV in 6/6 (100%)
2–5-fold lower antibody response than the 
Moraten live attenuated vaccine but 
comparable protection
[31]
Rabies Glycoprotein (G) Cynob nd Yes nd nd 2 doses of 10 g of DNA induced protective levels of 
antibody and protected against a lethal challenge with 
wild-type rabies virus in 4/4 (100%)
Comparable antibody responses and 
protection to a human diploid cell vaccine 
(HDCV)
[29]
A single dose of 8–60 g of DNA protected 3/5 (60%) 
macaques against lethal challenge with wild-type rabies 
virus 1 year post-immunization
ND [39]
Post-exposure vaccination with 60 g DNA in 
combination human rabies immunoglobulin protected 
2/4 (50%)
Post-exposure vaccination with 
HDCV + immunoglobulin protected 3/4 
(75%)
[65]
InXuenza HA of an H1N1 
inXuenza virus
Swine Yes Yes nd nd 2 doses of 9 g DNA reduced viral shedding and 
accelerated clearance in 8/8 following intranasal 
challenge with homologous virus
Induced about a 2-fold lower antibody than 
inactivated whole virus vaccine but similar 
protection
[66]
Smallpox A27L, A33R, L1R, B5R Rhesus Yes Yes nd nd Induced cross-neutralizing antibody against VACV and 
MOPV 
Survival and reduced disease severity in 3/3 macaques
Induced higher binding antibody and 
comparable neutralizing antibody but less 
protection when compared to the 
commercial smallpox vaccine (Dryvax)
[67,86]
RSV Porcine RRSV 
nucleoprotein
Swine Yes Yes nd nd PMED of 32 g of DNA into the skin of the ear was 
superior to delivery into oral tissues for induction of 
antibody
nd [68,87]
Vaccinated pigs developed a rapid recall antibody 
response following RRSV infection
RSV Porcine RRSV 
nucleoprotein (N) co-
delivered with IL-4 or 
IL-2
Swine Yes Yes nd Yes 3 doses of 60 g DNA reduced viral shedding and 
accelerated viral clearance in 12/12 following intranasal 
challenge with a Weld isolate. IL-2 enhanced T cell 
proliferation but not protection
nd [88]
Foot and 
mouth 
disease
FMD genome 
producing 
nonpathogenic virus 
particles
Swine Yes Yes nd nd 2 doses of 3 g DNA aVorded partial protection from 
highly virulent FMD challenge in 5/5
nd [89]
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responses in all or most vaccine recipients without adju-
vants or heterologous boosting with protein or viral vectors
(Table 5).
7.1. Dosing
The optimum DNA dosing regimen for PMED in
humans was determined in clinical trials employing a hepa-
titis B DNA vaccine expressing the surface antigen (sAg) of
HBV. These studies showed that a minimum of 1.0g and 2
delivery sites was required to induce a detectable response
in most subjects but higher responses and a better
responder rate could be achieved by increasing the dose to
4.0g DNA administered into 4 delivery sites [69,70]. A
subsequent HBsAg DNA vaccine study in pre-immune sub-
jects showed that increasing the DNA dose up to 8.0g (4
delivery sites) provided no additional beneWt, indicating
that a 4.0g DNA dose was suYcient for PMED in
humans.
7.2. Humoral responses
A PMED hepatitis B DNA vaccine trial was the Wrst to
demonstrate that DNA immunization could be used to
eVectively induce humoral responses in humans [69]. Immu-
nization with 3 doses of 1–4g of DNA induced robust
antibody in 100% of the immunized subjects at levels that
exceeded the minimum required for protective immunity
(10 mIU/ml). Clinical trials in pre-immune subjects also
showed that a single DNA vaccine dose was suYcient to
boost pre-existing hepatitis B and inXuenza-speciWc anti-
body responses [71,72]. In both of these studies, administra-
tion of a single dose of DNA by PMED increased antibody
responses at least 4–10-fold in the majority of subjects. In
the hepatitis B trial [72], a prototype commercial device
induced similar responses as a clinical research device that
had been used in earlier trials, supporting further develop-
ment of this device for future commercial purposes. In the
inXuenza trial [71], dose escalation showed that immuniza-
tion with 2.0 or 4.0g of DNA induced a higher responder
rate than immunization with 1.0g, an outcome that was
consistent with an earlier clinical trial employing a hepatitis
B DNA vaccine [69]. Importantly, the inXuenza study [71]
showed that a single immunization with just 2 or 4g of
DNA increased the number of subjects with seroprotective
levels of antibody against inXuenza from 5/24 (21%) to 22/
23 (96%), an outcome that suggests considerable promise
for development of this technology as an alternative strat-
egy for immunization against inXuenza.
Studies in mice showed that DNA immunization could
overcome non-responsiveness to vaccination with protein
vaccines [64]. A clinical trial in subjects non-responsive to
commercial hepatitis B protein vaccines was therefore con-
ducted to determine if particle-mediated DNA vaccines
could be similarly used to overcome vaccine non-respon-
siveness in humans [73]. Interestingly, a total of 9/12 sub-
jects that had previously failed to respond to 3–9 doses of
the commercial vaccine seroconverted and developed
protective levels of antibody after 1–3 DNA vaccine doses,
suggesting that PMED may be an attractive alternative
approach for prophylactic vaccination against hepatitis B.
7.3. Cell-mediated immune responses
The ability of particle-mediated DNA vaccines to
induce cell-mediated immune responses in humans has
been evaluated in 3 clinical trials. In the Wrst trial, a hepa-
titis B DNA vaccine induced signiWcant CD8+ and CD4+
T cell responses in 100% (12/12) of the subjects [69]. CD8+
T cell responses were MHC class I-restricted and demon-
strated both cytolytic and IFN eVector functions. CD4+
T cell responses were shown to be predominantly Th1 in
nature, an outcome that is consistent with HIV/SIV DNA
vaccine studies employing PMED in nonhuman primates
and argues against the hypothesis propagated through
mouse studies [52–56] that PMED induces a biased Th2
response.
In a second trial, a single dose of the hepatitis B DNA
vaccine boosted cell-mediated immune responses in indi-
viduals that were previously primed by vaccination with a
commercial hepatitis B protein vaccine [72]. A single DNA
immunization induced de novo CD8+ T cell responses in
several subjects and boosted CD4+ T cell responses in the
majority (70%), an outcome that was expected because the
individuals were primed by previous vaccination with the
hepatitis B protein vaccine for CD4+ but not CD8+ T cell
responses.
Particle-mediated DNA immunization has also been
tested in humans for the ability to induce T cell responses
in combination with heterologous boosting with a recom-
binant modiWed vaccinia Ankara vaccine (MVA) [74]. In
this trial, subjects were primed with a malaria DNA vac-
cine encoding the Plasmodium falciparum TRAP gene and
CTL epitopes by intramuscular injection of 1000 g of
DNA or by PMED of 4 g DNA and then boosted with
doses of MVA. A direct comparison of groups receiving
identical immunization regimens (i.e. 2 DNA priming
doses followed by 2 MVA boosting doses) showed a ten-
dency toward higher IFN T cell responses in the group
primed by particle-mediated delivery of DNA when
compared to the group primed by intramuscular DNA
injection (P D 0.10).
The ability of PMED to eVectively induce CD8+ and
CD4+ T cell responses in humans suggests this technology
will be useful for developing of novel vaccines or therapies
against cancers and chronic infectious diseases such as
AIDS and hepatitis B in which inducing or boosting
speciWc T cell responses is a goal.
7.4. Safety and tolerability
Clinical trials employing PMED have uniformly
demonstrated that the technology is safe and well-toler-
ated in humans (Table 5). PMED results in a painless
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Table 5
Particle-mediated DNA vaccines in human clinical trials
Pathogen/clinical phase DNA 
vaccine
Dose and regimen Immunogenicity and responder rate Safety and tolerability Comments Ref.
Antibody CD8 CD4
Hepatitis B
Phase I ascending pressure 
study in naÂ¨ve (N D 7)
sAg 0.25 g Yes (1/7) nd nd Safe and well-tolerated at all 
pressures
Protective levels of antibody 
(>10 mIU/ml) in 1/7
[70]
Hepatitis B
Phase I ascending dose 
study in naÂ¨ve (N D 12)
sAg 1.0 g (N D 4)
2.0 g (N D 4)
4.0 g (N D 4)
3 doses at weeks 0, 8, 
16
Yes (12/12) Yes (8/8) Epitope-speciWc 
CD8 were measured in 
only 8 of the 12 volunteers 
that were positive for the 
HLA-A2 MHC class I 
allele
Yes (12/12)
(Th1)
Transient skin reactions at 
delivery site include mild 
erythema, Xaking, and 
discoloration. Slight edema 
and itch. No discomfort
Protective levels of antibody 
(>10 mIU/ml) in 12/12
[69]
Highest dose (4.0 g) 
produced highest and most 
rapid antibody and CMI 
responses
Hepatitis B
Phase I in non-responders 
to licensed protein 
vaccine (N D 16)
sAg 4.0 g
3 doses at weeks 0, 8, 
16
Yes (12/16) nd nd Subjects report vaccination is 
painless with mild tingling 
minutes post-delivery
Protective levels of antibody 
(>10 mIU/ml) in subjects that 
had previously failed to 
respond to 3–9 
immunizations with licensed 
protein vaccine
[73]
Hepatitis B
Phase I in pre-immune with 
commercial device 
(N D 30)
sAg 4.0–8.0 g single dose 
with clinical research 
(XR1) or commercial 
(ND5.5) device
Yes (21/30)
>10-fold increase 
in antibody
Yes (low) Yes (21/30)
(balanced 
Th1/Th2)
Both devices safe and well-
tolerated
Transient, mild skin 
reactions similar in both 
devices. Mild discoloration 
persisted in some target sites 
for >6 months
No diVerence in magnitude 
of antibody, CMI response 
or number of responders 
between research and 
commercial device
[72]
Malaria
Phase I DNA prime-MVA 
boost in naÂ¨ve (N D 10)
TRAP and 
epitopes
2–3 doses of DNA 
alone and with 2 
booster doses of 
MVA
Not shown Yes (responder rate not 
shown)
Yes 
(responder 
rate not 
shown)
No antinuclear antibody 
responses detected
Particle-mediate DNA prime 
and MVA boost signiWcantly 
delayed the development of 
parasitemia
[74]
InXuenza
Phase I in pre-immune 
(N D 36)
HA 1.0 g (N D 12)
2.0 g (N D 12)
4.0 g (N D 12) Single 
dose
Yes (19/35)
>4-fold increase in 
antibody
nd nd Skin reactions followed for 
150 days. Reactions were 
mild and resolved after 14–28 
days except mild 
discoloration persisted in a 
few target sites for 180 days
Higher antibody and 
responder rate at higher 
DNA doses. 2–4 g doses 
increased the number of 
subjects with seroprotective 
levels of antibody from 5/24 
(21%) to 22/23 (96%)
[71]
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delivery of the DNA-coated gold particles into the skin.
Immediately after delivery, a transient, mild skin reaction
occurs that likely facilitates antigen uptake and process-
ing by antigen presenting cells (APC) through the pro-
duction of local cytokines that recruit APC to the
delivery site [33]. Reactions include mild redness, discol-
oration, Xaking, edema, rash, and/or itch. Consistent with
preclinical studies in swine, these reactions resolve within
14–28 days post-delivery, although a faint discoloration
can persist in some target sites for over 6 months post-
delivery [71,72].
8. Future prospects for PMED
The PMED device now being used in clinical trials is the
ND10, a single use, disposable design that is appropriate
for commercialization and large scale manufacture. It fea-
tures an internal helium cylinder and a cassette that holds
2g DNA coated on 1 mg gold particles. Depression of the
actuation button leads to release of the helium which bursts
the cassette membranes and delivers the gold particles into
the epidermis. The performance of the ND10 has been
shown to be equivalent to that of previous device models in
preclinical studies.
PMED DNA vaccination using the ND10 has several
important advantages for vaccine delivery. Administration
is needle-free thus avoiding any issues of needle stick injury
or disposal of sharps, and allowing vaccination of needle-
phobic subjects. For some applications self administration
may also be feasible. Once precipitated onto gold particles
the plasmid DNA is highly stable, allowing storage at room
temperature and deployment without a cold chain. Because
PMED uses only microgram quantities of DNA per admin-
istration, the DNA manufacture is easy to scale up and pro-
vision of product is rapid, giving the PMED technology a
competitive edge for responding to threats that demand a
quick response. Hence PMED vaccines for annual and pan-
demic inXuenza are especially attractive and, supported by
promising data from a phase I clinical trial of a PMED
DNA inXuenza vaccine [71], development of representative
annual and avian inXuenza vaccines is now underway.
PMED can also elicit protective responses to multiple anti-
gens expressed from mixtures of plasmid co-delivered in
one actuation [75]. The development of potent multicompo-
nent combination vaccines, capable of self administration
and room temperature storage, may be especially useful for
biodefense and a number of such vaccines are now being
studied.
In addition to these prophylactic targets, the ability of
PMED DNA vaccines to elicit potent cell mediated
responses has led to interest in the use of the technology for
therapeutic vaccination. Clinical trials are now underway
for therapeutic PMED DNA vaccines for HBV, HIV, Can-
cer, and HSV. Future development of these and other ther-
apeutic products is likely to focus on enhancement of
potency by inclusion of genetic adjuvants and novel dosing
regimens.
9. Summary
Early clinical studies employing parenteral needle deliv-
ery of DNA vaccines proved to be disappointing and led to
the general opinion that without heterologous boosting,
DNA vaccines would not be eVective in the clinic. In con-
trast, this review shows that DNA vaccines administered by
PMED, even in the absence of heterologous boosting or
adjuvants, have translated well from the mouse and bench
to preclinical large animal species, including nonhuman pri-
mates and pigs, and to human clinical trials. New improve-
ments in the PMED technology [72], vector design
[25,76,77], including co-formulation of PMED DNA vac-
cines with adjuvants [78], are in progress to further enhance
the potency of particle-mediated DNA vaccines. These
eVorts are expected to accelerate the commercialization of
PMED as an eVective approach for vaccination against
infectious diseases.
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